Subcutaneous Abatacept in Renal Transplant Recipients
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
After a kidney transplant, patients take drugs called anti-rejection drugs
(immunosuppressives) to prevent their bodies from rejecting the new kidney. At present it is
not possible to have a successful transplant without these drugs. These drugs make it
possible for a person who receives the transplant to accept the "foreign" kidney. Most
patients who get a transplant need to take anti-rejection medications for the rest of their
lives, or for as long as the kidney continues to work.
Researchers are looking to learn whether abatacept is as good as belatacept in preventing
rejection, whether there are other benefits or harms associated with abatacept treatment, and
possibly allows greater flexibility on patient's travel and time since abatacept is
self-administered at home.
This study is being done to answer these questions:
Are weekly abatacept injections under the skin a safe and effective substitute for monthly
belatacept intravenous (IV) infusions? and How well does the kidney function after switching
from belatacept to abatacept?
Phase:
Phase 1
Details
Lead Sponsor:
Idelberto Badell
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)